Literature DB >> 20546728

Polyglutamine-expanded ataxin-7 upregulates Bax expression by activating p53 in cerebellar and inferior olivary neurons.

Hung-Li Wang1, An-Hsun Chou, An-Chi Lin, Si-Ying Chen, Yi-Hshin Weng, Tu-Hsueh Yeh.   

Abstract

Spinocerebellar ataxia type 7 (SCA7) is an autosomal dominant neurodegenerative disease caused by polyglutamine-expanded ataxin-7. Prominent SCA7 neurodegeneration is found in the cerebellum and inferior olivary nucleus. Mutant polyglutamine ataxin-7 activated mitochondrial apoptotic pathway and induced apoptotic death of cerebellar and inferior olivary neurons by upregulating mRNA expression of proapoptotic Bax. In response to various cellular stresses, transcription factor p53 promotes neuronal apoptosis by enhancing the transcription of proapoptotic genes including Bax and Puma. Cellular and animal models of SCA7 were used to test the hypothesis that polyglutamine-expanded ataxin-7-Q52 upregulates Bax expression of cerebellar and inferior olivary neurons by enhancing transcriptional activity of p53. Electrophoretic mobility shift assay (EMSA) indicated that binding activity of p53 to Bax promoter sequence was significantly enhanced in cultured cerebellar neurons expressing mutant ataxin-7-Q52 and inferior olivary nucleus of transgenic mice expressing ataxin-7-Q52. The mRNA expression of Puma, a p53-inducible proapoptotic gene, was upregulated in cerebellar and inferior olivary neurons expressing ataxin-7-Q52. In the absence of significantly altered mRNA or protein expression of p53, mutant ataxin-7-Q52 increased the protein level of active phospho-p53(Ser15) in cerebellar and inferior olivary neurons. Our study provides the evidence that polyglutamine-expanded ataxin-7 upregulates the expression of Bax and Puma and causes apoptotic neuronal death by enhancing phosphorylation and transcriptional activity of p53. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20546728     DOI: 10.1016/j.expneurol.2010.05.011

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  15 in total

1.  Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration.

Authors:  Stephanie A Furrer; Mathini S Mohanachandran; Sarah M Waldherr; Christopher Chang; Vincent A Damian; Bryce L Sopher; Gwenn A Garden; Albert R La Spada
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

Review 2.  Intercellular (mis)communication in neurodegenerative disease.

Authors:  Gwenn A Garden; Albert R La Spada
Journal:  Neuron       Date:  2012-03-08       Impact factor: 17.173

3.  (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Authors:  C-Y Chen; Y-H Weng; K-Y Chien; K-J Lin; T-H Yeh; Y-P Cheng; C-S Lu; H-L Wang
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

Review 4.  Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.

Authors:  Melissa A C Ingram; Harry T Orr; H Brent Clark
Journal:  Brain Res Bull       Date:  2011-07-23       Impact factor: 4.077

5.  Coenzyme Q10 and spinocerebellar ataxias.

Authors:  Raymond Y Lo; Karla P Figueroa; Stefan M Pulst; Chi-Ying Lin; Susan Perlman; George Wilmot; Christopher Gomez; Jeremy Schmahmann; Henry Paulson; Vikram G Shakkottai; Sarah Ying; Theresa Zesiewicz; Khalaf Bushara; Michael Geschwind; Guangbin Xia; S H Subramony; Tetsuo Ashizawa; Sheng-Han Kuo
Journal:  Mov Disord       Date:  2014-12-01       Impact factor: 10.338

6.  Inhibition of autophagy via p53-mediated disruption of ULK1 in a SCA7 polyglutamine disease model.

Authors:  Xin Yu; Andrés Muñoz-Alarcón; Abiodun Ajayi; Kristin E Webling; Anne Steinhof; Ülo Langel; Anna-Lena Ström
Journal:  J Mol Neurosci       Date:  2013-04-18       Impact factor: 3.444

7.  Reduction of mutant ataxin-7 expression restores motor function and prevents cerebellar synaptic reorganization in a conditional mouse model of SCA7.

Authors:  Stephanie A Furrer; Sarah M Waldherr; Mathini S Mohanachandran; Travis D Baughn; Kien-Thiet Nguyen; Bryce L Sopher; Vincent A Damian; Gwenn A Garden; Albert R La Spada
Journal:  Hum Mol Genet       Date:  2012-11-29       Impact factor: 6.150

8.  Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.

Authors:  Rui Gao; Yongping Liu; Anabela Silva-Fernandes; Xiang Fang; Adriana Paulucci-Holthauzen; Arpita Chatterjee; Hang L Zhang; Tohru Matsuura; Sanjeev Choudhary; Tetsuo Ashizawa; Arnulf H Koeppen; Patricia Maciel; Tapas K Hazra; Partha S Sarkar
Journal:  PLoS Genet       Date:  2015-01-15       Impact factor: 5.917

Review 9.  Mouse models of polyglutamine diseases: review and data table. Part I.

Authors:  Maciej Figiel; Wojciech J Szlachcic; Pawel M Switonski; Agnieszka Gabka; Wlodzimierz J Krzyzosiak
Journal:  Mol Neurobiol       Date:  2012-09-07       Impact factor: 5.590

Review 10.  From pathways to targets: understanding the mechanisms behind polyglutamine disease.

Authors:  Jonasz Jeremiasz Weber; Anna Sergeevna Sowa; Tina Binder; Jeannette Hübener
Journal:  Biomed Res Int       Date:  2014-09-21       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.